TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20934702

Group type: EXPERIMENTAL
Intervention: Intervention group (42 nurses)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Waiting list group (38 nurses)
Number of subjects: 90
Study: 20120790

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplementation
Number of subjects: 843

Group type: COMPARATOR
Intervention: Iron‐folic acid supplementation
Number of subjects: 843
Study: 17121506

Group type: EXPERIMENTAL
Intervention: Intervention pharmacists received video-conference training on the management of depression and provided medication with extra advice and support.
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control pharmacists provided usual care.
Number of subjects: 106
Study: 15249281

Group type: EXPERIMENTAL
Intervention: Melatonin 1 mg nightly for 4 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo nightly for 4 weeks
Number of subjects: 26
Study: 11479064

Group type: EXPERIMENTAL
Intervention: Early detection (ED) system implemented in Rogaland, Norway
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual detection and referral systems in Ullevål, Norway, and Roskilde, Denmark
Number of subjects: 0
Study: 9126668

Group type: EXPERIMENTAL
Intervention: Plasma ascorbic acid concentration in smokers
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Serum urate concentration in non-smokers
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Plasma TRAP
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Lipid peroxidation resistance in serum or plasma
Number of subjects: 51
Study: 8482063

Group type: EXPERIMENTAL
Intervention: NSAID + misoprostol 200 mcg bid
Number of subjects: 95

Group type: COMPARATOR
Intervention: NSAID alone
Number of subjects: 95
Study: 3688315

Group type: EXPERIMENTAL
Intervention: Trimethoprim (200 mg) twice/day for 5 days
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Single dose of trimethoprim (600 mg)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 30757908

Group type: EXPERIMENTAL
Intervention: Nurse-led lipid-lowering intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study: 28715853

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rifampicin
Number of subjects: 0
Study: 25682550

Group type: EXPERIMENTAL
Intervention: Brexpiprazole 4 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brexpiprazole 1 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brexpiprazole 2 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brexpiprazole (1.23-1.89 kg weight gain)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brexpiprazole (4.2%-6.5%)
Number of subjects: 0
Study: 23565580

Group type: EXPERIMENTAL
Intervention: Benzocaine
Number of subjects: 13

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 13
Study: 21967319

Group type: EXPERIMENTAL
Intervention: Use of gel mat
Number of subjects: 100

Group type: COMPARATOR
Intervention: No gel mat
Number of subjects: 100
Study: 19922098

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) 200 microg once daily
Number of subjects: 500
Study: 17097752

Group type: EXPERIMENTAL
Intervention: H-FABP using the CardioDetect assay
Number of subjects: 108
Study: 15317401

Group type: EXPERIMENTAL
Intervention: Subcutaneous fondaparinux 2.5 mg once/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meta-analysis of fondaparinux
Number of subjects: 0
Study: 15515537

Group type: EXPERIMENTAL
Intervention: Shuanghuanglian
Number of subjects: 95

Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 95
Study: 9650328

Group type: EXPERIMENTAL
Intervention: Acarbose (200 mg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Plantago psyllium mucilage (15 g)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (only bread)
Number of subjects: 22
Study: 7661413

Group type: EXPERIMENTAL
Intervention: Continuous nebulization with albuterol (15 mg/hour)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metered-dose inhaler (MDI) with spacer device delivering albuterol
Number of subjects: 0
Study: 2797066

Group type: EXPERIMENTAL
Intervention: Furosemide (4 ml; 10 mg per milliliter)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 740584

Group type: EXPERIMENTAL
Intervention: Cyclical 'high-dose' oestrogens
Number of subjects: 62

Group type: COMPARATOR
Intervention: Cyclical 'low-dose' oestrogens
Number of subjects: 62

Group type: COMPARATOR
Intervention: Cyclical-sequential oestrogen/progestogen regimens
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Overall hormonal therapy
Number of subjects: 62
Study: 29316905

Group type: EXPERIMENTAL
Intervention: Smartphone-app intervention for 12 weeks
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 250
Study: 28776413

Group type: EXPERIMENTAL
Intervention: Qigong program (60 minutes)
Number of subjects: 26
Study: 26069178

Group type: EXPERIMENTAL
Intervention: Docetaxel, Cisplatin, and 5‐FU (TPF) induction chemotherapy followed by surgery
Number of subjects: 24

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 24
Study: 23380383

Group type: EXPERIMENTAL
Intervention: MRI-CT fusion-based sector analysis
Number of subjects: 50

Group type: COMPARATOR
Intervention: CT scans
Number of subjects: 50
Study: 21910821

Group type: EXPERIMENTAL
Intervention: Enoxaparin (0.5 mg/kg body weight)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Unfractionated Heparin (60 units/kg body weight)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Unfractionated Heparin (60 units/kg body weight) with concomitant use of acetylsalicylic acid (ASA)
Number of subjects: 210
Study: 19127909

Group type: EXPERIMENTAL
Intervention: Ziwu Liuzhu group
Number of subjects: 2

Group type: COMPARATOR
Intervention: Channel acupoint selection group
Number of subjects: 2

Group type: COMPARATOR
Intervention: Comparison between Ziwu Liuzhu group and Channel acupoint selection group
Number of subjects: 2
Study: 16457909

Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb (EZ) HTMV
Number of subjects: 1533

Group type: EXPERIMENTAL
Intervention: Connaught HTMV
Number of subjects: 1533

Group type: EXPERIMENTAL
Intervention: HTMV without DTP
Number of subjects: 1533

Group type: COMPARATOR
Intervention: HTMV with DTP
Number of subjects: 1533

Group type: COMPARATOR
Intervention: EZ HTMV
Number of subjects: 1533

Group type: EXPERIMENTAL
Intervention: HTMV without further DTP doses
Number of subjects: 1533
Study: 12629336

Group type: EXPERIMENTAL
Intervention: Combination pneumatic/ultrasonic lithotrite
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard ultrasonic device
Number of subjects: 20
Study: 10997757

Group type: EXPERIMENTAL
Intervention: Preventive measures (four different programs)
Number of subjects: 3373
Study: 9075663

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (750 mg/day) and endoscopic dilation of major duct stenoses
Number of subjects: 65
Study: 8245999

Group type: EXPERIMENTAL
Intervention: Uncemented fixation of the tibial component
Number of subjects: 34

Group type: COMPARATOR
Intervention: Cemented fixation of the tibial component
Number of subjects: 34
Study: 3527809

Group type: COMPARATOR
Intervention: 30 mg/kg i.v. dose of methylprednisolone sodium succinate (MPSS) followed by an identical dose three hours later in Study Group 2.
Number of subjects: 849
Study: 31654312

Group type: EXPERIMENTAL
Intervention: Drospirenone (DRSP) containing oral contraceptives (3 mg DRSP/30 mcg EE)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Chlormadinone acetate (CMA) containing oral contraceptives (2 mg CMA/30 mcg EE)
Number of subjects: 120
Study: 29502087

Group type: EXPERIMENTAL
Intervention: Early intervention group attended an antenatal diabetes clinic, commenced daily home blood glucose monitoring, and medication prescribed if lifestyle measures failed.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care with lifestyle education and a 75 g oral glucose tolerance test at 24 weeks' gestation.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early intervention group
Number of subjects: 0
Study: 26139491

Group type: EXPERIMENTAL
Intervention: Physiomesh/Securestrap (PH)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ventralight ST/SorbaFix (VS)
Number of subjects: 100
Study: 24576877

Group type: EXPERIMENTAL
Intervention: Macular GCIPL parameters (inferotemporal sector)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Peripapillary RNFL parameters (7 o'clock sector)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Optic nerve head parameters (rim area)
Number of subjects: 184
Study: 23225821

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 84

Group type: COMPARATOR
Intervention: Head-up tilt position
Number of subjects: 84
Study: 21999637

Group type: EXPERIMENTAL
Intervention: TELEmonitoring device for medication adherence support used for six months in addition to usual care.
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual care arm (control group).
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: TELEmonitoring device for medication adherence support.
Number of subjects: 400
Study: 18488807

Group type: EXPERIMENTAL
Intervention: Test formulation of spironolactone (100 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference formulation of spironolactone (100 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Test formulation of canrenone (active metabolite)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference formulation of canrenone (active metabolite)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Test and Reference formulations
Number of subjects: 20
Study: 17726806

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol 400 micrograms every 4 hours until termination of pregnancy
Number of subjects: 138

Group type: COMPARATOR
Intervention: Oral misoprostol 400 micrograms every 4 hours until termination of pregnancy
Number of subjects: 138
Study: 14739713

Group type: EXPERIMENTAL
Intervention: Class I antiarrhythmic drugs
Number of subjects: 13858

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 13858

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 13858

Group type: EXPERIMENTAL
Intervention: Electrical cardioversion
Number of subjects: 13858

Group type: COMPARATOR
Intervention: Control group (patients without AF)
Number of subjects: 13858
Study: 10896376

Group type: EXPERIMENTAL
Intervention: Experimental bandage system (Warm‐Up; Augustine Medical Inc, Eden Prairie, Minn)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional elastic bandage (Medipore Dress‐it; 3M, St Paul, Minn)
Number of subjects: 40
Study: 8881094

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Performance-based exposure treatment
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combined cognitive/performance treatment
Number of subjects: 48

Group type: COMPARATOR
Intervention: No-treatment control condition
Number of subjects: 48
Study: 1555416

Group type: EXPERIMENTAL
Intervention: Oxygen administration during apneas
Number of subjects: 6

Group type: COMPARATOR
Intervention: Breathing room air
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oxygen administration
Number of subjects: 6
Study: 3427251

Group type: EXPERIMENTAL
Intervention: Full contextual detail about the respondent and the event
Number of subjects: 48

Group type: COMPARATOR
Intervention: Edited version with only a basic outline of the event
Number of subjects: 48
Study: 29161376

Group type: EXPERIMENTAL
Intervention: One-phase treatment group (fixed appliance only)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Two-phase treatment group (removable appliance before fixed appliance)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Combined groups (boys)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Combined groups (patients with agenesis)
Number of subjects: 74
Study: 29071932

Group type: EXPERIMENTAL
Intervention: Cobalamin (1 mL) injection
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Gangliosides (1 mL) injection
Number of subjects: 90

Group type: COMPARATOR
Intervention: Routine medication and rehabilitation training (Control)
Number of subjects: 90
Study: 24990160

Group type: EXPERIMENTAL
Intervention: Acupuncture (12 treatments over 8 weeks, twice weekly for 4 weeks then once weekly for 4 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (treatment as usual)
Number of subjects: 20
Study: 22630807

Group type: EXPERIMENTAL
Intervention: IVR self-monitoring (24-week program)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Control (assessment-only condition)
Number of subjects: 185
Study: 19698041

Group type: EXPERIMENTAL
Intervention: Chronic hydrocephalus group (10 patients)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Atrophy group (8 patients)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Healthy volunteers (14 volunteers)
Number of subjects: 32
Study: 18243459

Group type: EXPERIMENTAL
Intervention: Attention cued to high spatial frequencies (SFs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attention cued to low spatial frequencies (SFs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control experiments manipulating the width of the attentional window
Number of subjects: 0
Study: 16321662

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 12728156

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone (0.15 mg/kg 6 hourly for 48 hours)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 10052766

Group type: EXPERIMENTAL
Intervention: GTR+DFDBA (bioabsorbable barrier + demineralized freeze-dried bone allografts)
Number of subjects: 12

Group type: COMPARATOR
Intervention: GTR (bioabsorbable barrier alone)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: GTR+DFDBA
Number of subjects: 12

Group type: COMPARATOR
Intervention: GTR
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 12
Study: 7566608

Group type: EXPERIMENTAL
Intervention: Renal imaging techniques (sonography and either tomography or CT scan)
Number of subjects: 598

Group type: COMPARATOR
Intervention: Daily use of analgesic mixtures for at least 5 years
Number of subjects: 598
Study: 2292540

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 140

Group type: COMPARATOR
Intervention: Amoxycillin
Number of subjects: 140
Study: 478543

Group type: EXPERIMENTAL
Intervention: Tactile and luminance degradation (four levels of luminance degradation and two levels of tactile restriction)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Standardized U.S. Navy work task (control condition)
Number of subjects: 5
Study: 31002283

Group type: EXPERIMENTAL
Intervention: Heat therapy (spa bathing at ∼39°C, 3‐5 days/wk for ≤30 min, followed by ≤30 min of callisthenics)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Supervised exercise (≤90 min of supervised walking and gym‐based exercise, 1‐2 days/wk)
Number of subjects: 22
Study: 28478854

Group type: EXPERIMENTAL
Intervention: Standardized preoperative stoma-education program
Number of subjects: 107
Study: 25171662

Group type: EXPERIMENTAL
Intervention: Adherence to BCRL self-care activities
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Adherence to BCRL self-care modalities
Number of subjects: 128
Study: 23583255

Group type: EXPERIMENTAL
Intervention: Exercise training plus simvastatin (40 mg/day)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Exercise training only
Number of subjects: 37
Study: 21778330

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg daily for 3 months)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 19801948

Group type: EXPERIMENTAL
Intervention: L-asparaginase (L-asp) therapy, median 5.5 doses (range: 1 to 20 doses)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: L-asparaginase (L-asp) therapy
Number of subjects: 192

Group type: COMPARATOR
Intervention: No L-asparaginase therapy (control group)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: High-risk chemotherapy regimen
Number of subjects: 192
Study: 16679506

Group type: EXPERIMENTAL
Intervention: Accelerometers
Number of subjects: 14

Group type: COMPARATOR
Intervention: Footswitches
Number of subjects: 14
Study: 15337213

Group type: EXPERIMENTAL
Intervention: Complex aortic plaques (44 persons)
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Simple aortic plaques (253 persons)
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Aortic atherosclerotic plaques (both simple and complex)
Number of subjects: 585
Study: 11748517

Group type: EXPERIMENTAL
Intervention: Nicardipine 0.015 mg/kg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Nicardipine 0.03 mg/kg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 9269506

Group type: EXPERIMENTAL
Intervention: Specific immunotherapy with modified Phleum pratense allergenic extracts
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (not treated with specific IT, only drugs)
Number of subjects: 10
Study: 8302441

Group type: EXPERIMENTAL
Intervention: Maximal upright bicycle exercise followed by supine rest for 60 min
Number of subjects: 9

Group type: COMPARATOR
Intervention: Non-exercise (control) day with upright position for 30 min followed by 60 min supine
Number of subjects: 9
Study: 3820353

Group type: EXPERIMENTAL
Intervention: Early massive excision of all full-thickness burns
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conservative therapy
Number of subjects: 50
Study: 28623465

Group type: EXPERIMENTAL
Intervention: Powered Toothbrush (PT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Manual Toothbrush (MT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both Toothbrushes (PT and MT)
Number of subjects: 100
Study: 26524706

Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 16492

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16492
Study: 24631986

Group type: EXPERIMENTAL
Intervention: Preoperative CFR in group 1 (mild renal failure)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Preoperative CFR in group 2 (no renal failure)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Postoperative CFR in group 1 (mild renal failure)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Postoperative CFR in group 2 (no renal failure)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Preoperative creatinine clearance
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Preoperative estimated GFR
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Postoperative day 7 creatinine clearance
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Postoperative month 6 creatinine clearance
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Postoperative day 7 estimated GFR
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Postoperative month 6 estimated GFR
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: CFR change after bypass surgery
Number of subjects: 52
Study: 24372434

Group type: EXPERIMENTAL
Intervention: Transurethral injection of Bulkamid®
Number of subjects: 52
Study: 20881485

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Innovative exercise training regimens
Number of subjects: 0
Study: 18455326

Group type: EXPERIMENTAL
Intervention: vdr-VMAT
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: cdr-VMAT
Number of subjects: 10

Group type: COMPARATOR
Intervention: IMRT
Number of subjects: 10

Group type: COMPARATOR
Intervention: 3D-CRT
Number of subjects: 10
Study: 16765428

Group type: EXPERIMENTAL
Intervention: Information on colorectal cancer risk factors
Number of subjects: 3185

Group type: EXPERIMENTAL
Intervention: Information on risk factors and colorectal screening
Number of subjects: 3185

Group type: COMPARATOR
Intervention: Control group (no information)
Number of subjects: 3185

Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 3185
Study: 12586796

Group type: EXPERIMENTAL
Intervention: ABVD
Number of subjects: 856

Group type: COMPARATOR
Intervention: MOPP/ABV
Number of subjects: 856
Study: 8734595

Group type: EXPERIMENTAL
Intervention: Talc coating on surfaces
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Water coating on surfaces
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sucrose coating on surfaces
Number of subjects: 10

Group type: COMPARATOR
Intervention: Untreated smooth surface
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Textured surfaces (with coatings)
Number of subjects: 10
Study: 1662595

Group type: COMPARATOR
Intervention: Nova T (Cu‐IUD)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Triphasic gestodene (OC)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Monthly norethisterone enanthate 50 mg + estradiol valerate 5 mg (injectable)
Number of subjects: 168
Study: 7114004

Group type: EXPERIMENTAL
Intervention: Indomethacin therapy (n = 13)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (n = 17)
Number of subjects: 55
Study: 30703494

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Fufang Danshen Dripping Pill (FDDP)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Combination of clopidogrel and FDDP
Number of subjects: 63
Study: 29663464

Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg (30 mg for dose reduction)
Number of subjects: 560

Group type: COMPARATOR
Intervention: Vitamin K antagonists (VKA)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging substudy
Number of subjects: 560
Study: 26812902

Group type: EXPERIMENTAL
Intervention: Working memory training
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Processing speed training
Number of subjects: 81

Group type: COMPARATOR
Intervention: No-training control group
Number of subjects: 81
Study: 24766750

Group type: EXPERIMENTAL
Intervention: Self-alcohol-related postings on Facebook
Number of subjects: 1

Group type: COMPARATOR
Intervention: Friends' alcohol-related postings on Facebook
Number of subjects: 1
Study: 22005174

Group type: EXPERIMENTAL
Intervention: Smoking cessation treatment (SCT)
Number of subjects: 528

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 528
Study: 20599140

Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) before therapy sessions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT) alone
Number of subjects: 0